David Perrin

An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin−/− mice and patients

Jian‐Sheng Lin, Yves Dauvilliers, Isabelle Arnulf et al. · Neurobiology of Disease · 2007 · 263 citations · Full text

Histamine H3 Receptor, Sleep Disorders, Sleep +13

BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, Hydrochloride], a Nonimidazole Inverse Agonist/Antagonist at the Human Histamine H3 Receptor: Preclinical Pharmacology

Xavier Ligneau, David Perrin, Laurent Landais et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 233 citations

Brain histamine and schizophrenia: Potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649

Xavier Ligneau, Laurent Landais, David Perrin et al. · Biochemical Pharmacology · 2007 · 104 citations · Full text

Psychiatry, Potential Therapeutic Applications, Medicine +15

Effect of enkephalins and morphine on insulin secretion from isolated rat islets

I. C. Green, David Perrin, KC Pedley et al. · Diabetologia · 1980 · 78 citations · Full text

Molecular Pharmacology, Neuropeptides, Medicine +11

Preclinical evaluation of the abuse potential of<scp>P</scp>itolisant, a histamine<scp>H</scp>₃receptor inverse agonist/antagonist compared with<scp>M</scp>odafinil

Marilyne Uguen, David Perrin, Simon Belliard et al. · British Journal of Pharmacology · 2013 · 55 citations · Full text